Holen Sie sich die Stockscreener-App
15.05
0.67%
0.10
Vorhandelsmarkt:
15.15
0.10
+0.66%
Schlusskurs vom Vortag:
$14.95
Offen:
$15.02
24-Stunden-Volumen:
477.85K
Relative Volume:
0.29
Marktkapitalisierung:
$624.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-112.46M
KGV:
-9.1768
EPS:
-1.64
Netto-Cashflow:
$-99.89M
1W Leistung:
-6.29%
1M Leistung:
+21.37%
6M Leistung:
-61.01%
1J Leistung:
-14.50%
1-Tages-Spanne:
$14.40
$15.48
1-Wochen-Bereich:
$14.40
$16.49
52-Wochen-Spanne:
$2.622
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
Firmenname
Vor Biopharma Inc
Sektor
Branche
Telefon
617-655-6580
Adresse
500 BOYLSTON STREET, BOSTON
Compare VOR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
15.05 | 620.72M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Eingeleitet | Citigroup | Buy |
| 2025-12-17 | Eingeleitet | TD Cowen | Buy |
| 2025-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2025-11-25 | Fortgesetzt | Wedbush | Neutral |
| 2025-10-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-09-24 | Hochstufung | Stifel | Hold → Buy |
| 2025-06-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | Eingeleitet | Wedbush | Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Neutral |
| 2021-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-12-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-25 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-03-03 | Eingeleitet | Evercore ISI | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Sell |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
Alle ansehen
Vor Biopharma Inc Aktie (VOR) Neueste Nachrichten
About Us | Oil & Gas JournalVor Biopharma Inc.Common Stock (Nasdaq:VOR) Stock Quote - FinancialContent
Guidance Update: Can Vor Biopharma Inc keep up with sector leadersTrade Exit Report & Reliable Breakout Forecasts - baoquankhu1.vn
Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Up 24.5% in February - MarketBeat
VOR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
VOR: Telitacicept advances in late-stage trials for MG and Sjögren's, targeting major autoimmune markets - TradingView
VOR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference - GlobeNewswire
Vor Bio schedules March 2 TD Cowen talk, investor meetings, webcast - Stock Titan
Pharma News: What are the analyst revisions for Vor Biopharma IncIs DMAC stock a good investment in YEARJuly 2025 Update & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Vor Biopharma Inc (VOR) Stock Price, Quote, News & History - Benzinga
[SCHEDULE 13G/A] Vor Biopharma Inc. Amended Passive Investment Disclosure - Stock Titan
Vor Bio Names Khan as Chief Medical Affairs Officer - Intellectia AI
Vor Bio Announces Inducement Grants in Compliance with Nasdaq Listing Rule 5635(c)(4) - Intellectia AI
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
VOR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
VOR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Vor Biopharma (NASDAQ:VOR) Stock Price Down 4%What's Next? - MarketBeat
Vor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune Therapy - MSN
Exit Recap: Can Vor Biopharma Inc. keep up with sector leadersJuly 2025 Opening Moves & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
VOR Stock Unaffected by Selling Stockholders' Actions - GuruFocus
Is Vor Biopharma Inc. gaining market shareDollar Strength & Real-Time Stock Price Movement Reports - mfd.ru
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Aug EndMonth: What is the PEG ratio of Vor Biopharma IncGap Down & High Conviction Trade Alerts - baoquankhu1.vn
Vor Biopharma Inc. (VOR) Presents at 44th Annual J.P. Morgan Healthcare ConferenceSlideshow - Seeking Alpha
VOR: TD Cowen Initiates Coverage with a 'Buy' Rating | VOR Stock News - GuruFocus
VOR: Telitacicept drives a global autoimmune strategy, backed by strong data, funding, and expert leadership - TradingView — Track All Markets
Quarterly Risk: How Vor Biopharma Inc stock valuations compare to rivals2025 Retail Activity & Weekly Top Performers Watchlists - Bộ Nội Vụ
Citigroup Initiates Coverage of Vor Biopharma (VOR) with Buy Recommendation - Nasdaq
Vor Biopharma (VOR) Receives New 'Buy' Rating From Citigroup | V - GuruFocus
Citigroup Begins Coverage on Vor Biopharma (NASDAQ:VOR) - MarketBeat
Citi Starts Vor Biopharma, Inc. (VOR) at Buy - StreetInsider
How Vor Biopharma Inc. stock responds to policy changes2025 EndofYear Setup & Growth Focused Investment Plans - ulpravda.ru
Will Vor Biopharma Inc. stock return to pre crisis levelsMarket Sentiment Report & Community Consensus Picks - ulpravda.ru
How Vor Biopharma Inc. stock valuations compare to rivals2025 Year in Review & High Accuracy Swing Entry Alerts - Улправда
Why Vor Biopharma Inc. stock remains a top recommendationTrade Volume Report & Stock Timing and Entry Methods - ulpravda.ru
Guidance Update: How Vor Biopharma Inc. stock responds to policy changes2025 Geopolitical Influence & AI Forecasted Stock Moves - Улправда
Why Vor Biopharma Inc. stock is a must watch in 2025Market Rally & Stepwise Entry and Exit Trade Signals - ulpravda.ru
How Vor Biopharma Inc. stock benefits from global expansionMonthly Performance Summary & Start Small. End Wealthy. - bollywoodhelpline.com
Vor Biopharma raises $42 million for cell therapy in leukemia | Biotechnology | The Pharmaletter - The Pharma Letter
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Autoimmune biotech Vor Bio to present at J.P. Morgan health conference - Stock Titan
What drives Vor Biopharma Inc stock priceInstitutional Buying Trends & Low Entry Cost Trading - earlytimes.in
Ariose Capital Management Ltd Invests $5.37 Million in Vor Biopharma Inc. $VOR - MarketBeat
Vor Biopharma Inc Stock Analysis and ForecastSell Signals and Alerts & Free High Yield Growth Strategies - earlytimes.in
Aug Macro: Will Vor Biopharma Inc stock outperform international peersFed Meeting & Verified Momentum Stock Watchlist - moha.gov.vn
Vor Biopharma CDO Departs, Transition Support Planned - TipRanks
Vor Biopharma Target of Unusually High Options Trading (NASDAQ:VOR) - MarketBeat
Portfolio Update: How Vor Biopharma Inc. stock benefits from global expansionTrade Risk Report & Fast Entry and Exit Trade Plans - moha.gov.vn
Vor Biopharma (VOR) Stock Jumps Over 30% After JPMorgan Upgrade: What December 2025’s Rally Really Means for Investors - ts2.tech
Gap Down: Is Vor Biopharma Inc stock positioned well for digital economyJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - moha.gov.vn
Finanzdaten der Vor Biopharma Inc-Aktie (VOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vor Biopharma Inc-Aktie (VOR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 28 '25 |
Sale |
27.42 |
124,311 |
3,408,230 |
1,055,749 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 30 '25 |
Sale |
25.12 |
24,579 |
617,424 |
779,652 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 27 '25 |
Sale |
28.12 |
90,941 |
2,557,261 |
1,180,060 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 23 '25 |
Sale |
28.01 |
76,880 |
2,153,409 |
1,324,346 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 24 '25 |
Sale |
28.01 |
53,345 |
1,494,193 |
1,271,001 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 20 '25 |
Sale |
29.67 |
92,023 |
2,730,483 |
0 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 21 '25 |
Sale |
28.11 |
25,027 |
703,509 |
1,401,226 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 17 '25 |
Sale |
30.25 |
25,717 |
777,987 |
1,178,725 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 20 '25 |
Sale |
30.05 |
11,616 |
349,101 |
1,167,109 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 21 '25 |
Sale |
30.07 |
200 |
6,015 |
1,166,909 |
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):